View multimedia presentations delivered by our internal experts and renowned external leaders

1. Learning Objectives
2. ADHD Genetics & Environment
3. ADHD Brain Structure & Function
4. ADHD Across the Lifespan
5. Development Phases & Trends
6. DSM-5 Criteria for ADHD
7. Transition of Care Adolescent to Adult
8. Why is Adult ADHD Missed
9. How does Adult ADHD Present
10. Comorbidities & IQ in Adult ADHD
11. Remission, Recovery & Persistence
12. Functional Impairments & Mortality
13. Diagnosis of Adult ADHD
14. Best Practices for Management
15. Summary

Diagnosing ADHD in adults brings substantially different considerations and challenges than it does for making the diagnosis in children. Renowned primary care psychiatry clinician, Dr. Brendan Montano guides you through the developmental trajectory of ADHD and patterns of impairments throughout the lifespan to better understand the clinical presentations and challenges of ADHD in adults.
This video is a recorded version of an educational webinar intended for health care professionals (HCPs). The content of the video, including but not limited to, the opinions expressed by the presenter, is solely that of the presenter. Tris Pharma, Inc. (Tris) had no control of the content or opinions expressed, with the exception to confirm that this educational webinar conforms to FDA regulations for communications with HCPs, other applicable laws, and Tris Guidelines for communications with HCPs. Tris did not seek to edit, guide, or influence content beyond ensuring, prior to the educational webinar, that this educational webinar conforms with controlling FDA regulations. Nothing contained herein should be considered a solicitation, promotion or advertisement for any Tris drug, including those under development. Any information contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by a physician or other HCP.

Dr. Montano is Director and Principal Investigator for CT Clinical Research in Cromwell, Connecticut, where he also holds a private practice in internal medicine, specializing in preventative medicine and mood disorders. In addition, he is an attending physician at Middlesex Hospital in Middletown, Connecticut.
Dr. Montano received his medical degree at the Albany Medical College of Albany, New York. He completed his residency in internal medicine at St. Francis Hospital and Medical Center in Hartford, Connecticut, and then trained as a resident in neurology, gastroenterology, and dermatology at Yale University in New Haven, Connecticut.

1. Introduction
2. Lsn 1: ADHD Etiology is Coded in our Genetic Code
3. Heritability of ADHD
4. Clinical Implications: High Heritability
5. Lsn 2: ADHD is Polygenic
6. ADHD Symptom Scores
7. Subthreshold Symptoms
8. ADHD Polygenic Risk in Adolescents
9. Clinical Implications: Symptoms & Polygenicity
10. Meta-Analysis of Subthreshold ADHD
11. Clinical Implications: Subthreshold Adult ADHD
12. Dimensionality and Diagnostic Errors
13. Sex Differences in Common Genetic Variants
14. Clinical Implications: Sex Differences
15. ADHD Polygenic Risk Correlates with Adversity
16. Clinical Implications: Adversity and ADHD
17. Parental Educ Correlates with ADHD Polygenic Risk
18. Clinical Implications: Parental Education and ADHD
19. Genomic Analysis of the Natural History of ADHD
20. Clinical Implications: Modern Environments & ADHD
21. Using DNA for Psychiatric Diagnosis
22. ADHD Polygenic Risk & Functional Outcomes
23. Clinical Implications: Functional Outcomes
24. Lsn 3: Psychiatric Comorbidity is Partly Genetic
25. Polygenicity and Genetic Correlations
26. Clinical Implications of Psychiatric Comorbidity
27. Lsn 4: ADHD Shares Genetics with Medical Condition
28. Genetic Correlations with Obesity/Lipids
29. Genetic Correlations with Other Traits
30. Clinical Implications of Somatic Comorbidity
31. Lsn 5: Genetics & Gene Expression in Brain
32. Partitioning Polygenic Risk by Tissue Group
33. Clinical Implications of ADHD as a Brain Disorder
34. Lsn 6: ADHD Genomics Clarify Onset and Persistence
35. Common Genetic Variants for Child and Adult ADHD
36. Persistent ADHD Associated w. High Poly Risk Score
37. Clinical Implications of Late Onset ADHD
38. Lsn 7: Genomic Discoveries Rethink Dx Practices
39. Pharmacogenetics Theory
40. Predict Drug Pharmacokinetics from DNA Variants
41. Predict Drug Response from DNA Variants
42. Clinical Utility: Pharmacogenetics of ADHD
43. Data Needed to Show Utility of PGT Kits
44. PGT and Depression
45. PGT Studies are Biased to Favor PGT
46. FDA View of PGT
47. Gene Testing for Antidepressant Efficacy
48. Pharmacogenetic Testing in Psychiatry
49. Un-intended Consequences of PGT
50. CPIC Link
51. Summary
52. Survey Link

The DSM reclassification of ADHD as a neurodevelopmental disorder brings with it enhanced understanding about the etiology, especially advances in the genetics of ADHD.

This video is a recorded version of an educational webinar intended for health care professionals (HCPs). The content of the video, including but not limited to, the opinions expressed by the presenter, is solely that of the presenter. Tris Pharma, Inc. (Tris) had no control of the content or opinions expressed, with the exception to confirm that this educational webinar conforms to FDA regulations for communications with HCPs, other applicable laws, and Tris Guidelines for communications with HCPs. Tris did not seek to edit, guide, or influence content beyond ensuring, prior to the educational webinar, that this educational webinar conforms with controlling FDA regulations. Nothing contained herein should be considered a solicitation, promotion or advertisement for any Tris drug, including those under development. Any information contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by a physician or other HCP.

Stephen Faraone, PhD, is a Distinguished Professor in the Departments of Psychiatry and Neuroscience & Physiology at SUNY Upstate Medical University and Vice Chair for Research in the Department of Psychiatry. He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Prof. Faraone studies the nature and causes of mental disorders in childhood and has ongoing research in psychiatric genetics, psychopharmacology, with a current focus on machine learning approaches to these areas.

An author on over 1000 journal articles, editorials, chapters and books, he was the eighth highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI, Science, 2000, Vol 288, pg 959). In 2005, ISI determined him to be the second highest cited author for Attention Deficit Hyperactivity Disorder. From 2014 to 2019 he has been listed as a highly cited researcher by Thomson Reuters/Clarivate Analytics. In 2019 and 2020, his citation metrics placed him in the top 0.01% of scientists across all fields. In 2021, expertscape indicated he was the top-rated expert in ADHD, worldwide. His lifetime H-Index as of August 2020 was 213.

Prof. Faraone is Editor for the journal Neuropsychiatric Genetic and Program Director of the educational website www.adhdinadults.com. He is President of the World Federation of ADHD and was a Founding Board member for the American Professional Society of ADHD and Related Disorders. He founded the ADHD Molecular Genetics Network in the 1990s and was a founding member of the Psychiatric Genomics Consortium’s Coordinating Committee.

In 2002, Prof. Faraone was inducted into the CHADD Hall of Fame in recognition of outstanding achievement in medicine and education research on attention disorders. In 2008, he received the SUNY Upstate President’s Award for Excellence and Leadership in Research. In 2009 he was awarded Alumni Fellow status at the University of Iowa in recognition of his outstanding contributions to society and his profession. In 2010 he received the Chancellor’s Award for Excellence in Scholarship and Creative Activities from the State University of New York. In 2013, he was awarded the title of Distinguished Professor by the State University of New York, which is conferred upon faculty having achieved national or international prominence and a distinguished reputation within the individual’s chosen field. In 2018 he received the Lifetime Achievement Award from the International Society of Psychiatric Genetics and in 2019 he received the Paul Hoch Award from the American Psychopathological Association.

1. Introduction
2. Objectives
3. Under-Treatment of Adult ADHD
4. Prevalence of Psychiatric Disorders in U.S. Adults
5. ADHD in Adults Age >50
6. Onset of Symptoms vs. Diagnosis
7. Neurobiology of ADHD
8. Neurocircuitry
9. Diagnostic Issues
10. Age of Diagnosis
11. Developmental Phases
12. Impairment Sources
13. Reporting Inattention/Hyperactivity with ASRS
14. Comprehensive Initial Adult Psych Eval for ADHD
15. Diagnostic Overlap
16. Executive Function
17. Neuropsychological Testing
18. Faking ADHD?
19. Complexities of Comorbidities
20. Symptom Overlaps in DSM V for Both ADHD and BPD
21. Nat’l Comorbidity Survey ADHD/Psych Disorders
22. ADHD+SUD
23. Stimulant Misuse and Diversion
24. ADHD has a Higher Risk of PTSD vs. Controls
25. Prioritization for Pharmacotherapy
26. Treatment Options and Medication
27. Benefits of ADHD Medication for Functional Outcome
28. Medication Consideration
29. Cognitive Effects of Stimulants
30. 30 Preparations for MPH or AMPH
31. Pharmacogenetic Testing in ADHD
32. ADHD Medication Sequencing
33. Side Effects with Stimulant Medication
34. Strategies for Safe Stimulant Prescription
35. Psychotherapies
36. Summary

ADHD in adults can be easily overlooked by clinicians, and the adults you treat may not be aware that they have ADHD either. Learn how to better recognize and treat ADHD in adults from Dr David Goodman, a premier international expert on adult ADHD.

This video is a recorded version of an educational webinar intended for health care professionals (HCPs). The content of the video, including but not limited to, the opinions expressed by the presenter, is solely that of the presenter. Tris Pharma, Inc. (Tris) had no control of the content or opinions expressed, with the exception to confirm that this educational webinar conforms to FDA regulations for communications with HCPs, other applicable laws, and Tris Guidelines for communications with HCPs. Tris did not seek to edit, guide, or influence content beyond ensuring, prior to the educational webinar, that this educational webinar conforms with controlling FDA regulations. Nothing contained herein should be considered a solicitation, promotion or advertisement for any Tris drug, including those under development. Any information contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by a physician or other HCP.

David W. Goodman, M.D. is Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. He is also Director of the Adult Attention Deficit Disorder Center of Maryland in Lutherville and Director of Suburban Psychiatric Associates, LLC. A 1983 graduate of Albany Medical College of Union University, Dr. Goodman completed a medical/psychiatric internship at Baltimore City Hospital and his psychiatric residency at The Johns Hopkins Hospital in 1986. Dr. Goodman has continued a full time clinical practice focusing on the diagnosis and treatment of mood disorders, adult Attention Deficit/Hyperactivity Disorder, Anxiety Disorders. For almost 30 years, he has been teaching psychiatric residents at The Johns Hopkins Hospital.

Dr. Goodman has presented over 600 lectures to primary care physicians, psychiatrists, medical specialists and the general public. His psychiatric commentary has been featured on national (ABC World News, CNN Anderson Cooper 360, ESPN Sports Center) and regional television around the country, PBS and national affiliate stations, national magazines (U.S. News and World Report, Wall Street Journal, New York Times, USA Weekend Magazine, Boston Globe, BusinessWeek) and radio interviews around the country. Dr. Goodman has been an ADHD consultant to Major League Baseball and now a consultant to the National Football League.

Dr. Goodman has been a Principal Investigator for multi-site Phase II and III drug trials for the treatment of adult Attention Deficit/Hyperactivity Disorder and Major Depression. Dr. Goodman is the lead author on the largest adult ADHD trial published and the lead author on the largest survey assessment of physician clinical practice for adults with ADHD. He has published articles in peer-reviewed journals, authored four book chapters and The Black Book of ADHD. He serves as a prepublication peer reviewer for several national and international psychiatric journals. He continues to treat patients in a full time clinical practice.

1. Introduction
2. Robert Caudill, MD
3. In-Person vs. Telehealth
4. Virtual Environment: What’s Lost?
5. Patient Selection
6. Past Barriers to Telemedicine
7. Current Barriers and Future of Telemedicine
8. Jon Evans, MS
9. Support for Telepsychiatry: Growing Need
10. Advantages of Telepsychiatry
11. Keys to Adopting/Expanding Telehealth
12. Tips for Integrating into Existing Workflow
13. CMS Regulatory Changes
14. Temporary Waiver of Ryan Height Act

COVID-19 led to significant changes in the way patient care is delivered and received. Join two telehealth experts as they provide their practical experience around the use and integration of telemedicine.

This video is a recorded version of an educational webinar intended for health care professionals (HCPs). The content of the video, including but not limited to, the opinions expressed by the presenter, is solely that of the presenter. Tris Pharma, Inc. (Tris) had no control of the content or opinions expressed, with the exception to confirm that this educational webinar conforms to FDA regulations for communications with HCPs, other applicable laws, and Tris Guidelines for communications with HCPs. Tris did not seek to edit, guide, or influence content beyond ensuring, prior to the educational webinar, that this educational webinar conforms with controlling FDA regulations. Nothing contained herein should be considered a solicitation, promotion or advertisement for any Tris drug, including those under development. Any information contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by a physician or other HCP.

Dr. Robert Caudill is a Professor of Psychiatry at the University of Louisville. He is the Residency Training Director with an interest in optimizing the role of technology in post-graduate medical education. He is also Director of Telemedicine and Information Technology Programs for the Department of Psychiatry. Dr. Caudill is a past chair for the Telemental Health Special Interest Group of the American Telemedicine Association and fellow in that organization. He is co-chair of the Telehealth Task Group of the National Network of Depression Centers. He is a distinguished fellow of the American Psychiatric Association and a founding member of its Committee on Telepsychiatry. Dr. Caudill completed his internship and psychiatric residency at the University of Louisville where he was a Chief Resident, President of the Psychiatric Residents’ Association and recipient of the department’s Award for Academic Excellence. Dr. Caudill received his board certification in psychiatry in 1995. He lectures on a number of topics related to technology, psychosocial rehabilitation, and psychopharmacology. Along with his faculty appointment, Dr. Caudill has served as a staff psychiatrist with several community mental health agencies in Kentucky.

Mr. Jon Evans received his Masters Degree in Clinical Psychology from Edinboro University of Pennsylvania and has been employed in the behavioral healthcare field for over 30 years. His career began at Hamot Institute for Behavioral Health where he was initially employed in the emergency department providing initial evaluations for patients presenting in the emergency room. In 1993, Mr. Evans became the founding President and CEO of Safe Harbor Behavioral Health. Safe Harbor was established to provide intensive outpatient services to patients with serious mental illness and to provide 24 hour a day crisis intervention services to anyone in Erie County. Through a SAMSHA Grant, Mr. Evans initiated and implemented a full time Tele-Psychiatry program at Safe Harbor Behavioral Health successfully enhancing access to care in the outpatient clinic. As a result of the successful implementation and patient outcomes, Mr. Evans founded InnovaTel Telepsychiatry in 2014 providing telepsychiatry coverage in multiple states in partnership with community provider organizations. Recently, the InnovaTel Telepsychiatry was endorsed as the premiere provider by National Council of Behavioral Health.

1. Introduction
2. Phase 1
3. Phase 2
4. Phase 3
5. Phase 4

Are you aware of the clinical trials that must be conducted before and after a pharmaceutical is FDA-approved? Watch this video for a quick overview of the four phases of clinical trials.

Dr. Everitt is a former Director, Field Medical Strategy for Tris Pharma. Her professional experience in CNS disorders began in 2008, which focused on ADHD, depression, bipolar disorder, and schizophrenia.

Previously, Dr. Everitt served as co-chief in a 2-year Global Medical Neuroscience Fellowship at Rutgers University. As adjunct faculty at Rutgers University College of Pharmacy, Dr. Everitt co-coordinated and taught Advanced Neuropsychiatry and Community Pharmacy Management.

She received her PharmD from Nova Southeastern University and earned her postdoctoral MS in Clinical Psychopharmacology at Fairleigh Dickinson University.